MedElevator
Войти в исследования International journal of vascular medicine · 2026
Serum Activin A Level and 1-Year Mortality in Atrial Septal Defect-Associated Pulmonary Artery Hypertension: A Case-Control Study From the COHARD-PH Registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rinastiti Pranindya, Hartopo Anggoro Budi, Cipta Cindy Elica, Maharani Syallom Gita, Anggrahini Dyah Wulan, Emoto Noriaki, Dinarti Lucia Kris
Аннотация
BACKGROUND: Serum activin A level is a promising prognostic biomarker for pulmonary artery hypertension (PAH). In this study, we aim to investigate serum activin A levels and their associations with 1-year mortality in atrial septal defect (ASD)-associated PAH patients.
METHODS: This was a case-control study of adult Indonesian patients diagnosed with ASD-PAH from the COHARD-PH registry. Cases were subjects deceased in a 1-year follow-up, whereas controls were those survived. Serum activin A was measured at the index of diagnosis. The demographics, clinical parameters, hemodynamic, and mortality data were retrieved from the registry database up to a 1-year follow-up period. These data were compared and analyzed between the case and control groups.
RESULTS: From the 1-year follow-up data, 44 cases (deceased group) and 102 controls (survived group) were identified. The deceased group had significant lower bodyweight (p < 0.001), body mass index (BMI) (p < 0.01), with higher NT-proBNP level (< 0.0001), higher proportion of Eisenmenger syndrome (p < 0.05), higher right atrial (RA) area (p < 0.0001), lower tricuspid annular plane systolic excursion (TAPSE) (p < 0.01), and a significant increase in mean right atrial pressure (mRAP) (< 0.0001). There was no difference in the activin A level between deceased and survivors (506.3 ± 259.1 pg/mL vs. 536.1 ± 293.9 pg/mL, p > 0.05, respectively). Moreover, activin A level did not associate with the mortality risk among subjects (OR = 0.9996; 95% CI: 0.9982-1.00087; p > 0.05).
CONCLUSION: Serum activin A level did not associate with 1-year mortality in adult patients with ASD-associated PAH.
METHODS: This was a case-control study of adult Indonesian patients diagnosed with ASD-PAH from the COHARD-PH registry. Cases were subjects deceased in a 1-year follow-up, whereas controls were those survived. Serum activin A was measured at the index of diagnosis. The demographics, clinical parameters, hemodynamic, and mortality data were retrieved from the registry database up to a 1-year follow-up period. These data were compared and analyzed between the case and control groups.
RESULTS: From the 1-year follow-up data, 44 cases (deceased group) and 102 controls (survived group) were identified. The deceased group had significant lower bodyweight (p < 0.001), body mass index (BMI) (p < 0.01), with higher NT-proBNP level (< 0.0001), higher proportion of Eisenmenger syndrome (p < 0.05), higher right atrial (RA) area (p < 0.0001), lower tricuspid annular plane systolic excursion (TAPSE) (p < 0.01), and a significant increase in mean right atrial pressure (mRAP) (< 0.0001). There was no difference in the activin A level between deceased and survivors (506.3 ± 259.1 pg/mL vs. 536.1 ± 293.9 pg/mL, p > 0.05, respectively). Moreover, activin A level did not associate with the mortality risk among subjects (OR = 0.9996; 95% CI: 0.9982-1.00087; p > 0.05).
CONCLUSION: Serum activin A level did not associate with 1-year mortality in adult patients with ASD-associated PAH.